"This is a clear improvement in the outcome, with increased PFS—by about 11 months—consistent improvement in response rate, and decreases in the development of metastatic disease," said lead investigator Luis Paz-Ares, MD, chair, Medical Oncology Department, Hospital Universitario Doce de Octubre.
A new tool is helping healthcare providers determine who will benefit from palliative care starting early in the course of their treatment for cancer, according to the authors of a pilot study whose results were presented Sept. 9, during the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.
Can a class of drugs commonly prescribed to help lower cholesterol levels protect against breast cancer? A study recently presented at the European Society of Cardiology conference in Barcelona, Spain, offers interesting results.
Medical staff from the Hackensack Meridian Health system joined patients, survivors and their families for a day of fun and entertainment sponsored by the John Theurer Cancer Center.
Fertility preservation might be a bit more difficult for women with breast cancer who test positive for the BRCA gene mutation.
The authors noted that although some studies have shown improvement in breast cancer outcomes from extending treatment with AIs beyond the initial 5 years after diagnosis, there is not much research on the toxicity profile of extended use.
People being treated for cancer often experience “sticker shock” when they learn what charges they will be responsible for paying and/or when they receive billing invoices.
Updated United States Preventive Services Task Force (USPSTF) guidelines on prostate cancer screening were recently published in Cancer.
Socio-psychological factors have moved into the forefront of patients' concerns regarding chemotherapy effects, surpassing nausea and vomiting, which previously ranked as the top concern.
A group of researchers led by a physician from Memorial Sloan Kettering Cancer Center in New York City examined the natural history and growth kinetics of low-risk papillary thyroid cancer (PTC), defined as intrathyroidal tumors ≤1.5 cm in size.
The FDA has approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).
Although they bring devastation to the whole community hit, catastrophes introduce a new level of difficulty for patients who are being treated for cancer.
Tisagenlecleucel (Kymriah), Novartis' newly approved CAR T-cell therapy, will be put on the market with a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and that Novartis characterized as well below a price level that could be justified on cost.
The FDA issued a historic approval of the first Chimeric Antigen Receptor (CAR) T-Cell Therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Francisco J. Esteva, M.D., Ph.D. discussed genomic testing at the 16th Annual International Congress on the Future of Breast Cancer® (East).
The FDA has approved fulvestrant (Faslodex) for use in hormone receptor (HR)-positive, HER2-negative locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
A patient can experience less pain, a quicker healing time and potentially more normal kidney function, due to the minimally invasive aspect of robotic surgery, according to Ketan K. Badani, M.D.
A California woman has been awarded $417 million after alleging that Johnson & Johnson’s talcum-based Baby Powder led to ovarian cancer. The jury award may be the largest yet concerning the product.
In some ways, it’s the down side of optimism: A recent study has found that older people sometimes think they are capable of more activity than their caregivers say they are.
Clinicians are aware of established guidelines for post-treatment surveillance and follow-up of people who have been treated for cancer. But what do patients expect?
Lynparza tablets (olaparib) tablets were granted FDA approval as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
Artist Ryan Berardi’s work goes way beyond pretty pictures. In fact, his 3D animations of what can go wrong during chemotherapy paint a horrific scene.
Bladder cancer is uncommon, and is more often diagnosed at an advanced stage because it has symptoms that mimic other disorders.
Physical activity may be effective in mitigating cancer-related cognitive impairment. Prior studies show this may be a promising treatment. However, sample sizes were small and self-reported measures varied.
The novel combination of a neurokinin-1 (NK-1) receptor antagonist and the 5-HT3 receptor antagonist palonosetron (Aloxi), NEPA (Akynzeo) had non-inferior efficacy compared to a conventional aprepitant regimen for preventing chemotherapy-inducted nausea and vomiting (CINV).
The FDA has approved CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, for adult patients with either newly-diagnosed therapy-related acute myeloid leukemia (t-AML) ot AML with myelodysplasia-related changes (AML-MRC).
Ibrutinib has been approved for the treatment of adult patients with chronic graft versus hose disease (GVHD) following the failure of 1 or more lines of systemic therapy.
The FDA has approved enasidenib for patients with IDH2-Mutated acute myeloid leukemia (AML).
